CD79A and nasopharyngeal carcinoma: It has been reported that the induced EBV-specific immune responses of NPC patients and EBV-IgA-VCA-positive individuals were decreased compared with normal people, suggesting that the EBV-specific cellular immune responses may be associated with the immunotherapy of NPC [37].